Hyphen BioMed
- Company typePrivate
- Founded1999
- HeadquartersNeuville-sur-oise, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Hyphen BioMed firmographics
Firmographics- Name
- Hyphen BioMed
- Legal name
- HYPHEN BioMed SASU
- Website
- https://hyphen-biomed.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Hyphen BioMed industry classification
Industry- Product category
- In Vitro Diagnostic Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (33911)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industry
- Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)
Keywords
Where Hyphen BioMed is headquartered
LocationHeadquarters
- HQ city
- Neuville-sur-oise
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Hyphen BioMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- In Vitro Diagnostic Reagent Sales: Sale of diagnostic reagents for blood coagulation, thrombosis, and auto-immunity testing. Products are available in ready-to-use or freeze-dried formats for automated or manual laboratory applications.
- Instrument and Accessory Sales: Sale of instruments and instrument-related accessories and consumables alongside reagents, as described in the terms and conditions of sale.
- Research Product Sales (RUO): Sale of Research Use Only (RUO) purified proteins, enzymes, recombinant proteins, chromogenic substrates, and ELISA kits for research applications.
- Calibrators and Controls: Sale of multi-calibrators, specific calibrators, and quality control plasmas for laboratory quality assurance.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Hyphen BioMed product offering
Product offeringCore offering
HYPHEN BioMed manufactures and sells in vitro diagnostic reagents for hemostasis, thrombosis, fibrinolysis, and auto-immunity disorders, offering more than 500 products across clotting, chromogenic, and ELISA methodologies. Products are available in ready-to-use or freeze-dried formats for automated or manual laboratory applications, sold globally through specialized distributors to hospital laboratories, medical researchers, and pharmaceutical companies. The portfolio is CE-IVD marked, FDA 510(k) cleared, and produced under ISO 13485:2016 and MDSAP quality systems.
Product overview
Hyphen BioMed is a Sysmex Group Company specializing in in vitro diagnostic medical devices for hemostasis science. The company offers over 500 products across multiple specialized product lines including BIOPHEN (chromogenic/clotting assays), ZYMUTEST (ELISA kits), ZYMUPHEN (immunoassays), HEMOCLOT (clotting assays), CEPHEN (lupus anticoagulant), FIBRIPHEN, PT-phen, and LIAPHEN. Product categories span Global & Routine Tests (PT, aPTT, Fibrinogen), Primary Hemostasis (platelet aggregation), Bleeding Disorders (hemophilia, vWD), Thrombophilia (AT, PC, PS, LA), Monitoring Anticoagulant (Anti-Xa, Anti-IIa), Fibrinolysis, Calibrators/Controls, Research-use-only products, and Auxiliary Reagents. The portfolio includes both CE-IVD and 510(k) cleared diagnostic reagents, with IVDR registration in process, available in ready-to-use or freeze-dried formats for automated or manual laboratory applications.
Differentiator
Problem solved
Functional benefit
Brands
- BIOPHEN: Product line for chromogenic and clotting assays for coagulation factors, heparin, and anticoagulant monitoring.
- ZYMUTEST
- ZYMUPHEN
- HEMOCLOT
- CEPHEN
- FIBRIPHEN
- PT-phen
- LIAPHEN
- AGGREGOMETRY
Products and services
- BIOPHEN Product Line Proprietary line of chromogenic and clotting assays for coagulation factor measurement, heparin and direct oral anticoagulant monitoring (Anti-Xa, Anti-IIa), and reference plasmas, including BIOPHEN NormalPlasma control. Available in ready-to-use or freeze-dried formats for automated or manual laboratory applications.
Quantifiable outcome
- 96/100 gender equality index score in 2025, demonstrating strong workplace practices.
Companies that use Hyphen BioMed
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Hyphen BioMed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature8 records
Hyphen BioMed partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Sysmex CorporationcoreSysmex Corporation is the parent company of Hyphen BioMed, as stated in the product catalog: 'Manufactured by HYPHEN BioMed a Sysmex Group Company.' This affiliation provides Hyphen BioMed with integration into the Sysmex group's global diagnostics ecosystem, including shared distribution channels (Sysmex Europe SE) and technological synergies in hematology and hemostasis diagnostics.
- Sysmex Europe SEcoreSysmex Europe SE, headquartered in Hamburg, Germany, serves as a key distributor for Hyphen BioMed products across multiple countries including Angola, Kuwait, Egypt, and other territories. The distributor contact details (Deelböge 19 D, 22297 Hamburg, Germany; +49 40 527 260; [email protected]; www.sysmex-europe.com) are listed in Hyphen BioMed's partner directory.
Scale indicators6 records
Recent moves1 record
Hyphen BioMed competitors and assessment
Company assessmentDirect peers
- Werfen (Instrumentation Laboratory): Specialized hemostasis and acute care diagnostics player with the ACL TOP analyzer family and hemostasis reagent portfolio (including HemosIL). Directly comparable to Hyphen BioMed in hemostasis product focus, clinical customer base, and proprietary assay technology.
- Helena Biosciences: Specialty hemostasis and thrombophilia diagnostics company offering reagent kits and analyzers. Comparable to Hyphen BioMed in therapeutic focus (thrombosis, lupus anticoagulant, factor deficiencies) and customer base of hospital hemostasis labs.
- Diagnostica Stago: France-based global leader in hemostasis and thrombosis diagnostics, manufacturing both coagulation analyzers and a comprehensive IVD reagent catalog. Stago is Hyphen BioMed's most direct competitor in the hemostasis specialty, especially across CE-IVD markets and hospital labs in Europe.
- Randox Laboratories: UK-based IVD manufacturer offering a broad reagent catalog including hemostasis and coagulation assays. Randox competes with Hyphen BioMed in specialty IVD reagents for clinical labs, with comparable product breadth across routine and specialty coagulation markers.
Broad incumbents
- Siemens Healthineers: Global diagnostics giant offering the INNOVANCE hemostasis reagent line alongside its Atellica coagulation analyzers. While serving a much broader diagnostics portfolio, Siemens competes head-to-head with Hyphen BioMed for hospital lab hemostasis reagent contracts worldwide.
- Roche Diagnostics: One of the largest global IVD players with cobas coagulation analyzers and a broad hemostasis reagent catalog. Roche competes with Hyphen BioMed across routine and specialty coagulation testing, leveraging scale and integrated instrument-reagent systems.
- Bio-Rad Laboratories: Clinical diagnostics manufacturer with quality controls and hemostasis reagents used by hospital and reference labs. While Bio-Rad's diagnostics focus is broader (controls, immunology, blood typing), it overlaps with Hyphen BioMed in the lab consumables and hemostasis reagents space.
- Abbott Diagnostics: Global diagnostics major offering hemostasis reagents and analyzers within a broad IVD and core lab portfolio. Competes with Hyphen BioMed in hospital laboratory hemostasis testing, though hemostasis is a smaller slice of Abbott's overall diagnostics business.
Others
- Sysmex Corporation: Parent company of Hyphen BioMed and a global leader in hematology and coagulation diagnostics with the CS-series analyzers. While Sysmex is the corporate parent, it is also a market participant whose hemostasis analyzers and reagents compete in the same labs Hyphen BioMed serves via its own catalog.
Emerging players
- HORIBA Medical: In vitro diagnostics subsidiary of HORIBA, offering hematology and clinical chemistry analyzers with associated reagent menus. Partially overlaps with Hyphen BioMed in hospital lab workflows, particularly where labs combine hematology and hemostasis testing.
Market position
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Hyphen BioMed social profiles
Digital presenceHyphen BioMed compliance and trust
Trust signalCompliance4 records
Hyphen BioMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hyphen BioMed leadership team
Management profileNumber of profiles
Profiles4 records
Hyphen BioMed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hyphen BioMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hyphen BioMed
What does Hyphen BioMed do?
HYPHEN BioMed manufactures and sells in vitro diagnostic reagents for hemostasis, thrombosis, fibrinolysis, and auto-immunity disorders, offering more than 500 products across clotting, chromogenic, and ELISA methodologies. Products are available in ready-to-use or freeze-dried formats for automated or manual laboratory applications, sold globally through specialized distributors to hospital laboratories, medical researchers, and pharmaceutical companies. The portfolio is CE-IVD marked, FDA 510(k) cleared, and produced under ISO 13485:2016 and MDSAP quality systems.
Is Hyphen BioMed a public or private company?
Hyphen BioMed is a private company. It is classified as corporate owned and is currently operating.
When was Hyphen BioMed founded?
Hyphen BioMed was founded in 1999. It employs 11 to 50 people.
Where is Hyphen BioMed based?
Hyphen BioMed is headquartered in Neuville-sur-oise, France, in the Europe region.
How does Hyphen BioMed make money?
Four revenue lines are on record. In Vitro Diagnostic Reagent Sales are the primary driver. The others are instrument and Accessory Sales, research Product Sales (RUO) and calibrators and Controls.
Who are Hyphen BioMed's main competitors?
Direct peers on record are Werfen (Instrumentation Laboratory), Helena Biosciences, Diagnostica Stago and Randox Laboratories. Broad incumbents are Siemens Healthineers, Roche Diagnostics, Bio-Rad Laboratories and Abbott Diagnostics. Sysmex Corporation is listed as an others. HORIBA Medical is listed as an emerging player.
Does Hyphen BioMed have an API?
No public API is recorded for Hyphen BioMed.
What industry is Hyphen BioMed in?
Hyphen BioMed's product category is In Vitro Diagnostic Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAALAH, Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing). Its NAICS code is 325413 and its SIC code is 2835.